SAMHSA Finalizes Additional Changes to the Confidentiality of Substance Use Disorder Patient Records Regulations

by Epstein Becker & Green

Epstein Becker & Green

  1. Executive Summary

On January 3, 2018, the Substance Abuse and Mental Health Services Administration (“SAMHSA”) published a final rule (“Final Rule”) to further update the Confidentiality of Substance Use Disorder Patient Records regulations (“Part 2 Regulations” or “Part 2”).[1] The Final Rule comes one year after SAMHSA’s publication of a prior final rule (“2017 Part 2 Rule”) that provided the first substantive update to the Part 2 Regulations since 1987.[2] The regulatory changes included in the 2017 Part 2 Rule are discussed in the Epstein Becker Green Client Alert titled “SAMHSA Finalizes Its Changes to the Confidentiality of Substance Use Disorder Patient Records Regulations.”[3]

Concurrent with its release of the 2017 Part 2 Rule, SAMHSA issued a supplemental notice of proposed rulemaking (“SNPRM”) to seek public comment on additional proposals not addressed in the 2017 Part 2 Rule, including circumstances under which lawful holders of substance use disorder (“SUD”) patient records and their legal representatives, contractors, and subcontractors may use and disclose patient identifying information for purposes of payment, health care operations, and audits and evaluations, as well as circumstances under which an abbreviated notice of the prohibition on re-disclosure should be used.[4]

The Final Rule addresses the proposed changes included in the SNPRM and attempts to better align the Part 2 Regulations with advances in the U.S. health care delivery system, while retaining privacy protections for individuals seeking treatment for SUDs. The changes in the Final Rule are effective on February 2, 2018, except that lawful holders of SUD patient records have until February 2, 2020, to ensure that their agreements with contractors, subcontractors, and legal representatives comply with the new requirements of 42 C.F.R. § 2.33(c).

  1. Overview of the Part 2 Regulations

The Part 2 Regulations, which implemented the federal drug and alcohol confidentiality law (42 U.S.C. § 290dd-2), protect the confidentiality of the identity, diagnosis, prognosis, or treatment of any patient records maintained in connection with the performance of any federally assisted program or activity relating to substance abuse education, prevention, training, treatment, rehabilitation, or research. The Part 2 Regulations apply to federally assisted programs that hold themselves out to the public as providing, and actually provide, SUD diagnosis, treatment, or referral for treatment, including identified units or medical personnel or other staff within a general medical facility. Part 2 also applies to other lawful holders of patient identifying information (e.g., individuals or entities that receive records pursuant to a Part 2-compliant patient consent).

  1. Details of SAMHSA’s Changes in the Final Rule
    1. Notice of Prohibition on Re-disclosure

Since their original publication, the Part 2 Regulations have required that covered parties making a disclosure of SUD records pursuant to a patient’s written consent must include with the disclosed records a written notice that the records are subject to Part 2 and that re-disclosure without additional patient consent is prohibited. In the Final Rule, SAMHSA adopted an abbreviated notice of the prohibition on re-disclosure that can be used in any instance in which a notice is required under 42 C.F.R. § 2.32. The abbreviated notice reads as follows: “Federal law/42 CFR part 2 prohibits unauthorized disclosure of these records.” The abbreviated notice is less than 80 characters long so that it fits within the standard free-text space in most electronic health record systems. In order to alleviate concerns that the abbreviated notice may be insufficient to convey understanding of the Part 2 requirements, SAMHSA encourages Part 2 programs and other lawful holders using the abbreviated notice to discuss the requirements with those to whom they disclose patient identifying information.

  1. Disclosures Permitted with Written Consent

The Final Rule makes a number of important changes to the rules governing the re-disclosure of elements of patient records by lawful holders of patient identifying information. These include efforts to align the process for re-disclosure of records necessary for payment and health care operations under Part 2 with the Health Insurance Portability and Accountability Act (“HIPAA”) regulations, to the extent possible.

  1. Disclosures by Lawful Holders

The Final Rule allows lawful holders to re-disclose the minimum amount of information necessary to contractors, subcontractors, and legal representatives for purposes of payment and health care operations. Although this provision is an attempt to align the re-disclosure rules with the HIPAA exception for health care operations, the Final Rule makes it clear that the Part 2 provision should be read more narrowly. In particular, SAMHSA added language to the regulatory text in 42 C.F.R. § 2.33(b) to clarify that disclosures to contractors, subcontractors, and legal representatives are not permitted to carry out other purposes, such as activities related to patient diagnosis, treatment, or referral for treatment. As such, although lawful holders will now be able to re-disclose certain information, such re-disclosures must be narrowly restricted to information necessary for payment and health care operations.

  1. List of Payment and Health Care Operations Activities

In the SNPRM, SAMHSA proposed a list of 17 distinct payment and health care operations activities for which a lawful holder of patient identifying information would be allowed to re-disclose the minimum amount of information necessary without additional patient consent. In the Final Rule, SAMHSA removed the list from the regulatory text but included it, unaltered, in the preamble as a non-exhaustive, illustrative list of the types of permissible payment and health care operations activities that would justify re-disclosure. As such, SAMHSA expressly acknowledges that the re-disclosure of other appropriate payment and health care operations activities may be permitted by lawful holders. 

Although many commenters requested that SAMHSA include care coordination, case management, and other “treatment-related” activities on the list of activities for which re-disclosure is allowed, SAMHSA refused to do so in the Final Rule. Instead, SAMHSA added an explicit statement to the regulatory text to make clear that re-disclosures to carry out activities related to SUD patient diagnosis, treatment, or referral for treatment are not permissible payment or health care operations activities. In this key aspect, the re-disclosure provisions are more restrictive than those in the HIPAA Privacy Rule (which allows for the disclosure of information for treatment, payment, or health care operations, and which includes case management and care coordination activities under its definition of “health care operations”).

In addition to the list of payment and health care operations activities included in the preamble to the Final Rule, SAMHSA intends to allow for re-disclosures of Part 2 patient identifying information for other “appropriate” payment and health care operations activities. As such, lawful holders should carefully review the reasons why they would like to share Part 2 information to determine if re-disclosure can be supported as a permissible payment or health care operations activity.

Payment and Health Care Operations
Activities Included in the SNPRM

  • Billing, claims management, collections activities, obtaining payment under a contract for reinsurance, claims filing and related health care data processing;
  • Clinical professional support services (e.g., quality assessment and improvement initiatives; utilization review and management services);
  • Patient safety activities;
  • Activities pertaining to:
  • The training of student trainees and health care professionals,
  • The assessment of practitioner competencies,
  • The assessment of provider and/or health plan performance, and
  • Training of non-health care professionals;
  • Accreditation, certification, licensing, or credentialing activities;
  • Underwriting, enrollment, premium rating, and other activities related to the creation, renewal, or replacement of a contract of health insurance or health benefits, and ceding, securing, or placing a contract for reinsurance of risk relating to claims for health care;
  • Third-party liability coverage;
  • Activities related to addressing fraud, waste and abuse;
  • Conducting or arranging for medical review, legal services, and auditing functions;
  • Business planning and development, such as conducting cost-management and planning related analyses related to managing and operating, including formulary development and administration, development or improvement of methods of payment or coverage policies;
  • Business management and general administrative activities, including management activities relating to implementation of and compliance with the requirements of this or other statutes or regulations;
  • Customer services, including the provision of data analyses for policy holders, plan sponsors, or other customers;
  • Resolution of internal grievances;
  • The sale, transfer, merger, consolidation, or dissolution of an organization;
  • Determinations of eligibility or coverage (e.g., coordination of benefit services or the determination of cost sharing amounts), and adjudication or subrogation of health benefit claims;
  • Risk adjusting amounts due based on enrollee health status and demographic characteristics; [and]
  • Review of health care services with respect to medical necessity, coverage under a health plan, appropriateness of care, or justification of charges [5]
  1. Contract Provisions for Disclosures Under Section 2.33(c)

In the SNPRM, SAMHSA stated that it was critical that “contractors, subcontractors, and legal representatives understand their obligations with respect to [Part 2] patient identifying information.” To that end, in the Final Rule, SAMHSA adopted requirements for lawful holders that contract with third parties to carry out payment and health care operations to include specific language in the contract with such parties addressing compliance with Part 2 requirements. Under circumstances where no such contract exists, a separate, comparable legal instrument may be used to require that the contractor, subcontractor, or voluntary legal representative be bound by the provisions of Part 2 upon receipt of patient identifying information.

In the Final Rule, SAMHSA removed a proposed requirement that the contract must specify the permitted uses of patient identifying information by the contractor, subcontractor, or voluntary legal representative. In doing so, SAMHSA noted that 42 C.F.R. § 2.13 already requires that any disclosure must be limited to that information which is necessary to carry out the purpose of the disclosure. SAMHSA also noted that lawful holders should ensure that the purpose section of the patient consent form is consistent with the role of, or services provided by, the contractor or subcontractor (e.g., “payment and health care operations”) in order to comply with 42 C.F.R. § 2.13.

Further, while commenters proposed the inclusion of specific contract language under 42 C.F.R. § 2.33(c), SAMHSA declined to require or provide specific contract language to be used between the parties, stating that lawful holders need the flexibility to include language that fits within their contract structures. The Final Rule gives lawful holders until February 2, 2020, to bring their contracts and legal instruments with contractors, subcontractors, and legal representatives into compliance with the requirements of 42 C.F.R. § 2.33(c).

  1. Other Comments Concerning Disclosures by Lawful Holders

In response to the SNPRM, SAMHSA received other miscellaneous comments regarding disclosures by lawful holders. SAMHSA issued the following responses to these comments, providing a number of key clarifications:

  • Patient identifying information can be disclosed directly to a lawful holder’s contractor or subcontractor and does not need to first be disclosed to the lawful holder (i.e., the recipient named on the consent form) and then subsequently re-disclosed, as long as the information is being used for the purposes of payment and health care operations.
  • Lawful holders who wish to disclose patient identifying information pursuant to 42 C.F.R. § 2.33(b) must enter into a written contract with the contractor (or appropriate comparable legal instrument in the case of a legal representative retained voluntarily by the lawful holder). When there is a legal representative who is required to represent the lawful holder by law, the requirement for a contract or comparable legal instrument in 42 C.F.R. § 2.33(c) does not apply.
  • The consent requirement under 42 C.F.R. § 2.33(b) applies only to lawful holders that receive patient identifying information pursuant to a written consent. Accordingly, the ability to re-disclose that information to contractors, subcontractors, or legal representatives does not apply to qualified service organizations (“QSOs”). Further, SAMHSA clarified that a QSO is not permitted “to re-disclose information to a third party unless that third party is a contract agent of the QSO, helping them provide services described in the [QSO agreement], and only as long as the agent only further discloses the information back to the QSO or to the [P]art 2 program from which it came.”
  1. Disclosures for Audits and Evaluations

The Part 2 Regulations at 42 C.F.R. § 2.53 include procedures for federal, state, or local government agencies providing financial assistance to a Part 2 program to have access to patient records, without a patient’s consent, in order to audit and evaluate activities, such as financial and quality assurance functions critical to accountable care organizations and other health care organizations.

The Final Rule clarifies that patient identifying information may be disclosed to individuals or entities that perform audits and evaluations on behalf of federal, state, and local governments providing financial assistance to, or regulating the activities of, lawful holders as well as Part 2 programs. If disclosures are made to an individual or entity under this section for a Medicare, Medicaid, or Children’s Health Insurance Program audit or evaluation, including a civil investigation or administrative remedy, further disclosures may be made to the individual’s or entity’s contractors, subcontractors, or legal representatives to carry out the audit or evaluation. In addition, audits and evaluations may be performed by individuals or entities on behalf of third-party payers or quality improvement organizations, or their contractors, subcontractors, or legal representatives. Patient identifying information disclosed for purposes of an audit or evaluation may be disclosed back only to the Part 2 program or other lawful holder from which it was obtained and may be used only to carry out an audit or evaluation purpose or to investigate or prosecute criminal or other activities, as authorized by a court order entered under 42 C.F.R. § 2.66.

SAMHSA received comments expressing concern that permitting re-disclosure to contractors and subcontractors for purposes of carrying out an audit or evaluation (i) greatly increases the number of individuals who may receive protected information, (ii) could lead to patient records being used for risk adjustment and reporting purposes, and (iii) could impact a patient’s health coverage or health score. SAMHSA responded that it will take requests for additional safeguards and restrictions under advisement for potential future rulemaking, and it cautioned that patient identifying information disclosed pursuant to an audit may be used only for audit and evaluation purposes.

  1. Requests for Public Comment and Additional Opportunities for Stakeholder Input

In the SNPRM, SAMHSA requested public comment on a number of policy issues related to Part 2. These included the mechanism to convey the scope of the written consent to lawful holders and their downstream entities, a range of other restrictions and safeguards, and the implications of the proposed revisions for the privacy and confidentiality of SUD patient records in general.

  1. Conveying the Scope of the Written Consent

The 2017 Part 2 Rule amended the Part 2 Regulations to permit patients to include a general designation for individuals and/or entities with a treating provider relationship (e.g., “my treating providers”) in the “To Whom” section of the consent form in order to allow for their records to be disclosed to any such providers. This was a significant revision to the preexisting regulations, which required that each provider be specifically named on the consent form. However, the 2017 Part 2 Rule provided that the amount and kind of SUD treatment information that may be disclosed must be expressly specified on the consent form. This could be specified broadly (e.g., “all my substance use disorder information”) or more granularly (e.g., medications, substance use history, employment information, living situation, and/or social supports). The SNPRM sought public comment on how to best effectuate the communication of the scope of written consent to Part 2 programs, lawful holders, and their downstream entities.

In the Final Rule, SAMHSA clarified that the consent form itself is not required to accompany the Part 2 records as a part of a disclosure or allowed re-disclosure. Otherwise, the Final Rule did not provide any additional clarification on the required mechanism for conveying the scope of the authorization. As such, Part 2 programs, lawful holders, and their downstream entities should ensure compliance with the required notice of the prohibition on re-disclosure and otherwise must determine the best way to communicate the scope of the underlying written consent. One of the most important aspects of the scope of consent that should be communicated is whether a particular consent covers all, or only a subset, of the information in the record.

  1. Other Restrictions and Safeguards

In response to the SNPRM, SAMHSA received a number of comments regarding the establishment of appropriate restrictions and safeguards in various circumstances in order to maintain the core protections afforded to patients’ SUD records under Part 2. In general, commenters expressed concern that broader dissemination of a patient’s treatment information could lead to that information becoming known by friends, family, employers, insurers, and other providers of medical services, which, in turn, could lead to negative consequences for the patient, such as loss of employment, loss of housing, loss of child custody, discrimination by medical professionals and insurers, and arrest, prosecution, and incarceration.

SAMHSA did not adopt additional restrictions or safeguards in the Final Rule. The agency states that the existing restrictions and safeguards are adequate, including provisions limiting the use of patient identifying information in criminal and civil procedures and requiring that any disclosure made under the Part 2 Regulations must be limited to that information which is necessary to carry out the purpose of the disclosure. However, SAMHSA did identify a number of areas on which it may consider additional rulemaking in the future, including adding a notification to patients on the consent form indicating that they are consenting to the disclosure of their patient identifying information to both the recipient and the recipient’s contractors, subcontractors, and legal representatives to carry out payment or health care operations; adding mechanisms to enable individuals who have been adversely impacted by an improper disclosure to identify the source of a disclosure, including the addition of a List of Disclosures requirement for contractors, subcontractors, and legal representatives; and strengthening language regarding a patient’s right to file a grievance or complaint.

  1. Stakeholder Meeting

Consistent with the mandate in the 21st Century Cures Act, prior to March 21, 2018, the Secretary of Health and Human Services will convene relevant stakeholders to determine the effects of the Part 2 Regulations on patient care, health outcomes, and patient privacy.[6] This meeting will provide stakeholders with an additional opportunity to provide input to SAMHSA regarding implementation of Part 2, including changes adopted in the Final Rule, and will inform the course of future Part 2 rulemaking. The stakeholder meeting will include a discussion on the scope of re-disclosure by lawful holders authorized by the Final Rule.

  1. Conclusion

SAMHSA expects that the changes made in the Final Rule will enhance information sharing and the efficiency of such payment and health care operations as claims processing, business management, training, and customer service and will facilitate audit and evaluation activities. Further, SAMHSA expects that the re-disclosure provisions will make it easier for some Part 2 programs and other lawful holders to use electronic health record systems and will reduce regulatory burdens. Accordingly, Part 2 programs and other lawful holders need to be aware of how the additional changes in the Final Rule impact their ability to comply with the Part 2 Regulations. They also need to continue to be mindful of how the Part 2 requirements differ from other health privacy laws, such as HIPAA. Finally, they should continue to engage with SAMHSA through the forthcoming stakeholder meeting and through future rulemaking efforts to ensure that the Part 2 Regulations provide appropriate flexibility in allowing for disclosures of Part 2 patient identifying information while continuing to maintain the confidentiality of SUD patient records.


[1] 83 Fed. Reg. 239 (Jan. 3, 2018), available at

[2] See 82 Fed. Reg. 6052 (Jan. 18, 2017).

[4] See 82 Fed. Reg. 5485 (Jan. 18, 2017).

[5] 83 Fed. Reg. at 243.

[6] See Pub. L. 114-255 (enacted Dec. 13, 2016). Section 11002 requires the stakeholder meeting to be held prior to March 21, 2018.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Epstein Becker & Green | Attorney Advertising

Written by:

Epstein Becker & Green

Epstein Becker & Green on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at:

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit
  • New Relic - For more information on New Relic cookies, please visit
  • Google Analytics - For more information on Google Analytics cookies, visit To opt-out of being tracked by Google Analytics across all websites visit This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at:

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.